COL11A1 provides valuable information about the tumor microenvironment and may assist in: confirming stromal invasion in diagnostically uncertain cases (e.g., DCIS or ADH), assessing recurrence risk, and evaluating response to antistromal therapies [6]. This evidence concerns the gene COL11A1 and neoplasm.